미국 · 보도자료 · Nexalin Technology, Inc. · 2026-10-08 12:30
나스닥 최소 입찰가 요건 회복, 상장 유지 승인 획득
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs
